The Best Healthcare Stock to Invest $1,000 in Right Now

Core Viewpoint - Teva Pharmaceutical Industries has significantly outperformed Eli Lilly in stock price growth, with Teva's shares more than doubling over the past year, while Lilly's shares have only gained around 14% [1][2]. Financial Performance - Teva reported fourth-quarter revenue of $4.7 billion, reflecting an 11% year-over-year increase, and adjusted earnings per share (EPS) of $0.96, surpassing analyst expectations of $0.64 [3]. - For the full year, Teva achieved a revenue growth of 5% and a non-GAAP earnings growth of 19% [3]. - However, $500 million in milestone payments from Sanofi for the drug candidate duvakitug skewed the quarterly and annual results, as excluding these payments showed only modest revenue and earnings growth compared to 2024 [4]. Strategic Shift - Teva is transitioning from a long-time focus on generic drugs to specialty drugs, with strong sales from branded products like Austedo, Ajovy, and Uzedy currently offsetting stagnant generics sales [5]. - This strategic pivot is expected to lead to an increased share of specialty drugs in Teva's revenue mix, which should enhance revenue, margins, and earnings growth in the future [5]. Valuation and Investment Outlook - Teva's stock is currently trading at approximately 12.5 times forward earnings, which is on the middle to lower end of the valuation range for pharmaceutical stocks [6]. - For long-term investors, there remains an opportunity for growth, as the company's transformation has not yet been fully reflected in its stock valuation, and potential acceleration in growth starting in 2027 could lead to both earnings growth and multiple expansion [7].